News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,346 Results
Type
Article (14045)
Company Profile (283)
Press Release (249018)
Section
Business (79418)
Career Advice (152)
Deals (13210)
Drug Delivery (34)
Drug Development (50375)
Employer Resources (31)
FDA (5697)
Job Trends (5120)
News (144234)
Policy (10022)
Tag
Academia (901)
Alliances (21589)
Alzheimer's disease (783)
Antibody-drug conjugate (ADC) (70)
Approvals (5681)
Artificial intelligence (90)
Bankruptcy (99)
Best Places to Work (4549)
Biotechnology (233)
Breast cancer (123)
Cancer (1038)
Cardiovascular disease (84)
Career advice (132)
CAR-T (85)
Cell therapy (247)
Clinical research (40416)
Collaboration (398)
Compensation (155)
COVID-19 (1018)
C-suite (104)
Cystic fibrosis (72)
Data (1073)
Diabetes (96)
Diagnostics (1227)
Drug discovery (64)
Earnings (29076)
Events (47461)
Executive appointments (325)
FDA (6139)
Funding (376)
Gene editing (71)
Gene therapy (186)
GLP-1 (333)
Government (1069)
Healthcare (6560)
Infectious disease (1059)
Inflammatory bowel disease (100)
IPO (7229)
Job creations (859)
Job search strategy (127)
Layoffs (192)
Legal (1379)
Lung cancer (154)
Manufacturing (93)
Medical device (2566)
Medtech (2567)
Mergers & acquisitions (6183)
Metabolic disorders (296)
Neuroscience (1077)
NextGen: Class of 2025 (2013)
Non-profit (851)
Northern California (1240)
Obesity (161)
Opinion (93)
Parkinson's disease (85)
Patents (71)
People (25271)
Phase I (14269)
Phase II (18793)
Phase III (11885)
Pipeline (458)
Postmarket research (852)
Preclinical (5983)
Radiopharmaceuticals (208)
Rare diseases (230)
Real estate (1411)
Regulatory (8374)
Research institute (932)
Series A (74)
Southern California (1112)
Startups (1968)
United States (9811)
Vaccines (176)
Weight loss (94)
Date
Today (118)
Last 7 days (358)
Last 30 days (1521)
Last 365 days (20441)
2025 (1521)
2024 (20553)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (17038)
Australia (2881)
California (2830)
Canada (889)
China (254)
Colorado (105)
Connecticut (118)
Europe (36649)
Florida (319)
Georgia (84)
Illinois (177)
Indiana (68)
Maryland (370)
Massachusetts (2242)
Minnesota (113)
New Jersey (704)
New York (778)
North Carolina (449)
Northern California (1240)
Ohio (91)
Pennsylvania (534)
South America (207)
Southern California (1112)
Texas (315)
Washington State (271)
263,346 Results for "tranquis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Tranquis Therapeutics Announces Participation in March 2022 Investor Conferences
Tranquis Therapeutics announced that members of its management team will participate in the following investor conferences in March 2022:
March 22, 2022
·
1 min read
Drug Development
Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022
Tranquis Therapeutics, Inc. today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1 a, at ARDD 2022, the 9th Aging Research and Drug Discovery meeting, taking place August 29 to September 2, 2022 at the University of Copenhagen, Denmark.
August 29, 2022
·
2 min read
Drug Development
Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis
Tranquis plans to start a Phase 2 trial in people living with ALS by the end of 2022.
June 21, 2022
·
3 min read
Drug Development
Tranquis Therapeutics Announces Initiation of Phase 1 Study of TQS-168
Tranquis Therapeutics today announced the initiation of dosing in a Phase 1 clinical study of TQS-168 in healthy volunteers.
December 8, 2021
·
3 min read
Drug Development
Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168
Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the completion of its Phase 1 clinical trial of TQS-168, a small molecule modulator of PGC-1a in development for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
June 2, 2022
·
3 min read
Biotech Bay
Tranquis Therapeutics to Present at Biotech Showcase and Participate in BIO @ JPM Partnering Conference
Tranquis Therapeutics announced its CEO, Sanjak Kakkar, M.D. will give a corporate presentation at the Biotech Showcase, being held January 10-19, 2022.
January 4, 2022
·
1 min read
Drug Development
Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168 for the Treatment of ALS at Neuroscience 2021 Annual Meeting
Tranquis Therapeutics, today announced it presented positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN).
November 3, 2021
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Tranquis Therapeutics Strengthens Leadership Team with Additions of Janet Hurt, MPH, as SVP of Clinical Evidence Generation and Faisal Shawwa, MBA, as SVP of Finance
Tranquis Therapeutics today announced it has strengthened its management team with the addition of Faisal Shawwa, MBA, as Senior Vice President of Finance and Administration and Janet Hurt, MPH, as Senior Vice President of Clinical Evidence Generation.
December 1, 2021
·
3 min read
Business
Tranquis Therapeutics Strengthens Leadership Team with Appointments of Frederic Godderis as Chief Operating Officer and Jonas Hannestad, MD, PhD, as Chief Medical Officer
Tranquis Therapeutics, a private immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced that it has strengthened its management team
May 26, 2021
·
5 min read
1 of 26,335
Next
